Skip to main content

Table 4 Phase 2 trials of ofatumumab monotherapy and chemoimmunotherapy in CLL patients

From: Therapeutic advancement of chronic lymphocytic leukemia

Reference (year) Regimen Number of patients Treatment status CR,% ORR,% Median PFS (months) Median OS (months)
Wierda, 2010 [36] Ofatumumab 95 FA-ref 0 51 5.5 14.2
   111 BF-ref 2 44 5.5 17.4
Flinn, 2011 [37] Ofatumumab 42 Untreated 0 44 NR NR
Wierda, 2011 [38] O-FC (500 mg) 31 Untreated 32 77 NR NR
  O-FC (1000 mg) 30 Untreated 50 73 NR NR
Shanafelt, 2011 [39] PCO 33 Untreated 45 94 NR NR
  1. Abbreviations: BF-ref, fludarabine-refractory CLL with bulky (>5 cm) lymphadenopathy; CR, complete response; FA-ref, fludarabine- and alemtuzumab-refractory; NR, not researched; O-FC (500 mg), 500 mg ofatumumab combined with fludarabine and cyclophosphamide; O-FC (1000 mg), 1000 mg ofatumumab combined with fludarabine and cyclophosphamide; ORR, overall response rate; OS, overall survival; PCO, pentostatin, cyclophosphamide and ofatumumab.